0001493152-26-009549
SEC filingLifeMD, Inc. reported fiscal year 2025 results with $194.1 million in telehealth revenue, generating $166.3 million in gross profit (85.7% gross margin). The company recorded an operating loss from continuing operations of $7.7 million and a net loss from continuing operations of $10.2 million. However, net income from discontinued operations of $25.9 million resulted in overall net income of $15.6 million and net income attributable to common stockholders of $11.2 million. The company generated $8.3 million in operating cash flow and ended the year with $36.8 million in cash from continuing operations. Total assets stood at $70.4 million with total liabilities of $47.3 million, resulting in stockholders' equity of $23.2 million. The results reflect the impact of discontinued operations on overall profitability while continuing operations remained unprofitable.
LifeMD, Inc. reported fiscal year 2025 results with $194.1 million in telehealth revenue. The company generated $166.3 million in gross profit, representing an 85.7% gross margin. Continuing operations resulted in an operating loss of $7.7 million and a net loss of $10.2 million. However, discontinued operations contributed $25.9 million in net income, leading to overall net income of $15.6 million. After accounting for non-controlling interests and preferred stock dividends, net income attributable to common stockholders was $11.2 million. The company maintained a strong cash position with $36.8 million in cash from continuing operations at year-end, up from $33.1 million total cash at the beginning of the period.
The company's revenue is derived entirely from telehealth services, with $194.1 million in net telehealth revenue for fiscal year 2025. No segment breakdown or geographic mix is provided in the available data. The revenue figure represents the net amount after any adjustments or allowances. The cost of telehealth revenue was $27.7 million, resulting in the $166.3 million gross profit. No information is provided about revenue growth drivers, customer concentration, or pricing strategies in the provided data.
LifeMD achieved an 85.7% gross margin on its telehealth revenue, with $166.3 million in gross profit from $194.1 million in revenue. Operating expenses totaled $174.0 million, including $86.1 million in selling and marketing expenses, $57.9 million in general and administrative expenses, $11.6 million in customer service expenses, $11.1 million in other operating expenses, and $7.3 million in development costs. This resulted in an operating loss margin of -4.0% from continuing operations. The net loss margin from continuing operations was -5.3%. Stock compensation expense was $10.5 million, representing a significant non-cash component of expenses.
The company generated $8.3 million in net cash from operating activities, including $2.1 million from continuing operations and $6.2 million from discontinued operations. Investing activities provided $6.9 million in net cash, primarily from discontinued operations, while financing activities used $13.4 million in net cash. The balance sheet shows total assets of $70.4 million, including $51.8 million in current assets and $18.6 million in non-current assets. Total liabilities were $47.3 million, with $41.6 million in current liabilities. Stockholders' equity was $23.2 million, with an accumulated deficit of $228.6 million offset by $251.5 million in additional paid-in capital. The company had $8.4 million in current portion of convertible debt and $9.9 million in long-term convertible debt.
No forward-looking statements, management guidance, strategic priorities, or specific risk factors are provided in the available data. The filing does not include management's discussion and analysis section that would typically contain outlook information. The financial data presented focuses solely on historical results for fiscal year 2025 without projections for future periods. Investors should refer to the complete 10-K filing for any forward-looking information that may be included in sections not provided in this data extract.